IP Library › Granted Patent US 11,026,909
Granted Patent B1
US 11,026,909 · App. 17/132,602 · Granted Jun 8, 2021

Therapy for viral infections including the novel corona virus (COVID-19)

Inventors: Nadimpally Satyavarahala Raju (Hyderabad, IN); Venkata Satya Suresh Attili (Hyderabad, IN); Nadimpally Neha Varma (Hyderabad, IN); Steven Jerome Moore (Newtown, CT); Cullen Thomas Moore (Newtown, CT)
A61K31/197A61K9/02A61K31/375A61K31/5415A61K33/30A61K36/9066
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,026,909
App. No.
17/132,602
Granted
Jun 8, 2021
Kind
B1
Abstract

A method for amelioriation of, or prophylaxis against, a viral infection comprising administering to a patient in need of treatment a therapeutically effective amount of 5 aminolevulinic acid, optionally with at least one of cucumarin nano, zinc, vitamin C and methylene blue, and compositions thereof. Such compositions may be used for the treatment of coronavirus infections, including the SARS-CoV-2 virus, and/or rhinoviruses.

Claims (20)

1. A pharmaceutical composition comprising 5-aminolevulinic acid and at least one of curcumin nano, zinc, vitamin C and methylene blue, or pharmaceutically acceptable salt thereof, each present in therapeutically effective amounts, in an admixture with pharmaceutically acceptable excipient.

2. The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid, curcumin nano, and Vitamin C.

3. The pharmaceutical composition of claim 2 wherein the composition is an oral dosage form.

4. The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid, curcumin nano, Vitamin C, and zinc.

5. The pharmaceutical composition of claim 4 wherein the composition is an oral dosage form.

6. The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid, curcumin nano, and zinc.

7. The pharmaceutical composition of claim 6 wherein the composition is an oral dosage form.

8. The pharmaceutical composition of claim 1 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof.

9. The pharmaceutical composition of claim 1 wherein the therapeutic dose of 5-aminolevulinic acid is 100 mg-1600 mg provided in a single or divided doses of twice daily or thrice daily, the therapeutic dose of curcumin nano is 100 mg-1000 mg provided in a single or divided doses of twice daily or thrice daily, the therapeutic dose of Vitamin C is 80 mg-1000 mg provided in a single or divided doses of twice daily or thrice daily, the therapeutic dose of zinc is 5 mg-150 mg provided in a single or divided doses of twice daily or thrice daily, and the therapeutic dose of methylene blue is 50 mg-250 mg provided in a single or divided doses of twice daily or thrice daily.

10. The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid and methylene blue.

11. The pharmaceutical composition of claim 9 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof.

12. The pharmaceutical composition of claim 1 , comprising 5-aminolevulinic acid and zinc.

13. The pharmaceutical composition of claim 12 wherein the composition is an oral dosage form.

14. The pharmaceutical composition of claim 12 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof.

15. The pharmaceutical composition of claim 1 wherein the composition comprises 5-aminolevulinic acid, and curcumin nano.

16. The pharmaceutical composition of claim 15 wherein the composition is an oral dosage form.

17. The pharmaceutical composition of claim 15 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof.

18. The pharmaceutical composition of claim 1 , comprising 5-aminolevulinic acid and vitamin C.

19. The pharmaceutical composition of claim 18 wherein the composition is an oral dosage form.

20. The pharmaceutical composition of claim 18 wherein the 5-aminolevulinic acid is 5-ALA hydrochloride or 5 ALA-phosphate, or combination thereof.

Continuity (1)
Division 16920000 · Jul 2, 2020
Cited By (1)
US 12,357,667